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Purpose: G protein-coupled receptors (GPCRs) are a superfamily of membrane proteins of vast pharmaceutical
interest. Here, we describe a graph theory-based analysis of the structure of the β2 adrenergic receptor (β2 AR), a
prototypical GPCR. In particular, we illustrate the network of direct and indirect interactions that link each amino
acid residue to any other residue of the receptor.
Methods: Networks of interconnected amino acid residues in proteins are analogous to social networks of
interconnected people. Hence, they can be studied through the same analysis tools typically employed to analyze
social networks – or networks in general – to reveal patterns of connectivity, influential members, and dynamicity.
We focused on the analysis of closeness-centrality, which is a measure of the overall connectivity distance of the
member of a network to all other members.
Results: The residues endowed with the highest closeness-centrality are located in the middle of the seven
transmembrane domains (TMs). In particular, they are mostly located in the middle of TM2, TM3, TM6 or TM7, while
fewer of them are located in the middle of TM1, TM4 or TM5. At the cytosolic end of TM6, the centrality detected
for the active structure is markedly lower than that detected for the corresponding residues in the inactive structures.
Moreover, several residues acquire centrality when the structures are analyzed in the presence of ligands. Strikingly,
there is little overlap between the residues that acquire centrality in the presence of the ligand in the blocker-bound
structures and the agonist-bound structures.
Conclusions: Our results reflect the fact that the receptor resembles a bow tie, with a rather tight knot of closely
interconnected residues and two ends that fan out in two opposite directions: one toward the extracellular space,
which hosts the ligand binding cavity, and one toward the cytosol, which hosts the G protein binding cavity. Moreover,
they underscore how interaction network is by the conformational rearrangements concomitant with the activation of
the receptor and by the presence of agonists or blockers.
Keywords: G protein-coupled receptor (GPCR); β2 adrenergic receptor (β2 AR); Graph theory; Networks;
Closeness-centrality; Non-covalent interactionsBackground
G protein-coupled receptors (GPCRs) are a large group of
integral membrane proteins of paramount pharmaceutical
interest (Overington et al. 2006). Topologically, they feature
a single polypeptide chain that spans the plasma membrane
seven times, with seven α-helical transmembrane domains
(TMs, numbered from TM1 to TM7). The N-terminus* Correspondence: costanzi@american.edu
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in any medium, provided the original work is pis in the extracellular milieu, the C-terminus is in the
cytosol, and the seven TMs are connected by three
extracellular loops (ELs, numbered from EL1 to EL3)
and three intracellular loops (ILs, numbered from IL1
to IL3). In recent years, the field of GPCR crystallography
has experienced a rapid expansion (Costanzi et al. 2009;
Hanson and Stevens 2009; Stevens et al. 2013; Rosenbaum
et al. 2009; Shukla et al. 2008; Lefkowitz et al. 2008), which
is currently fostering the structure-based discovery of
novel ligands for the receptors endowed with experimen-
tally elucidated structures (Costanzi 2011; Mason et al.
2012; Jacobson and Costanzi 2012). Moreover, the entiren Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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in structural knowledge, since the experimentally solved
structures can serve as templates for the construction
of computational models of those receptors that have
yet to be solved experimentally (Costanzi 2010, 2012,
2013; Costanzi 2011; Costanzi and Wang 2014). This
boom of GPCR crystallography led to the publication
of several computational analyses intended to elucidate
the molecular architecture of the receptors and/or probe
the applicability of the three-dimensional structures to
drug discovery (Jacobson and Costanzi 2012; Katritch
et al. 2012, 2013; Venkatakrishnan et al. 2013; Mason
et al. 2012).
In light of the wealth of information that surrounds
it, we elected the β2 adrenergic receptor (β2 AR) as a
model system for many of our computational studies of
the GPCR superfamily (Costanzi and Vilar 2012; Vilar
et al. 2011b; Vilar et al. 2011a; Vilar et al. 2010; Pooput
et al. 2009). The (β2 AR) is a GPCR naturally activated
by epinephrine and targeted by FDA approved drugs for a
variety of indications (Pierce et al. 2002). In particular,
blockers of the β2 AR are primarily employed as drugs
for the treatment of hypertension, while agonists of the
same receptor are chiefly used for the treatment of asthma
(Johnson and Liggett 2011; Tashkin and Fabbri 2010).
Among all GPCRs, the β2 AR is one of the most studied
and better understood members of the superfamily, and is
also the one for which the widest variety of experimentally
elucidated structures have been solved (Kobilka 2011;
Shukla et al. 2008; Lefkowitz et al. 2008). In particular, a
total of 12 structures of the β2 AR were solved in
complex with 7 different ligands (Rasmussen et al.
2007; Cherezov et al. 2007; Rosenbaum et al. 2007;
Hanson et al. 2008; Bokoch et al. 2010; Wacker et al.
2010; Rosenbaum et al. 2011; Rasmussen et al. 2011a;
Rasmussen et al. 2011b). Although most of the struc-
tures have been solved in an inactive state, two of the
crystal structures of the β2 AR have been solved in a
fully activated state, one in complex with a G protein-
heterotrimer (PDB ID: 3SN6) and one in complex with
a nanobody that mimics the G protein (PDB ID: 3P0G)
(Rasmussen et al. 2011a; Rasmussen et al. 2011b). Of note,
the 2012 Nobel Prize in Chemistry was awarded to Robert
Lefkowitz and Brian Kobilka for their pioneering and
fundamental contributions to the current understanding
of the structure and function of the β2 AR (Lefkowitz
2013; Kobilka 2013).
Here, we analyze the structure of the β2 AR through
graph theory, a technique that has recently emerged as
a tool applicable to the study of the global structural
aspects of proteins (Di Paola et al. 2013; Amitai et al.
2004; Thibert et al. 2005; Tang et al. 2008; Slama et al.
2008; Pathak et al. 2013; del Sol et al. 2006a; Chea and
Livesay 2007; del Sol et al. 2006b). In this approach,protein structures are described as a graph consisting of a
number of nodes, i.e. the amino acid residues that make
up the protein, connected by edges, i.e. the non-covalent
interactions occurring between the residues (Figure 1a-c).
Just like members of a social network, each residue of a
protein has a certain number of first-degree connections,
i.e. residues in direct contact, a certain number of second-
degree connections, i.e. residues that are not in direct
contact but share a common residue with which they
are both in contact. Ultimately, each residue of the
receptor is connected with every other residue of the
receptor, although with different degrees of connectivity.
This network of interconnected residues can be studied
through the same analysis tools employed to analyze social
networks of interconnected people, revealing patterns of
connectivity, influential members, and dynamic behavior.
Notably, in a seminal study published in 2006, Nussinov
and coworkers applied graph theory to the study of
rhodopsin, when this was still the only GPCR with an
experimentally elucidated three-dimensional structure
(del Sol et al. 2006b). In particular, the authors represented
the structure of rhodopsin as a network of interacting
residues and, removing residues from the network, identi-
fied those that play key roles in maintaining long-range
interactions between distal regions of the receptor.
In this work, we focused on the analysis of the centrality
of the various residues that compose the β2 AR, identify-
ing the residues endowed with the highest centrality,
comparing how the centrality of the same residues varies
in structures that were solved in the inactive or the
activated state, and studying the changes in centrality
when the same structure was analyzed in the presence
or the absence of the co-crystallized ligand.
The centrality of a member of a network is a measure
of the extent to which the member in question is connected
with other members of the network. There are several
metrics to measure the centrality of the members of a
network. Here, we specifically studied closeness-centrality,
which is defined as the overall connectivity distance
of the member in question (a node in the graph that
represents the network) to all other members of the
network (all other nodes in the graph). Mathematically,
the closeness-centrality (C) of node x can be derived
through the formula shown in Figure 1d, and results in
a positive number that can assume the maximum value
of 1, for nodes directly connected with every other node
in the graph (Amitai et al. 2004).
In social networks, highly connected individuals tend
to have a high influence on society (Wasserman and Faust
1994). Equally, residues endowed with high closeness-
centrality have been found to be critical for the function of
enzymes and to be generally located in the catalytic sites
(Amitai et al. 2004; Thibert et al. 2005; Tang et al. 2008;
Slama et al. 2008; Pathak et al. 2013; del Sol et al. 2006a;
Figure 1 Five interconnected residues in the carazolol-bound structure of the β2 AR (PDB ID: 2RH1). Panel a: a three-dimensional atomic
model of the five residues, with dotted double headed arrows indicating the shortest physical distance between Asp 113 and its neighboring
residues and cyan lines indicating residues that establish contacts according to the CSU analysis; the residues are shown in balls and sticks format,
with carbon atoms colored in gray, oxygen atoms in red, nitrogen atoms in blue and hydrogen atoms in white. Panel b: a graph representation
in which the five residues are shown as nodes, with edges connecting the residues that establish contacts according to the CSU analysis. Panel c:
physical distance between the closest atoms of Asp 113 and each other shown residue (represented as dotted double headed arrows in panel a) and
connectivity distance between Asp 113 and each of the other residues shown, as inferred from the graph. All connectivity distances are calculated
along the shortest paths. For instance, the green edge in panel a shows the shortest path from node 1 to node 3, while the red edges show
an alternative longer path. Panel d: mathematical formula for the calculation of closeness-centrality (C) of node x, where n = number of nodes
in the graph; d(x, y) = geodesic connectivity distance, i.e. the shortest path, between node x and node y; U = the set of all nodes. If the four
shown residues were the only four nodes in the graph representation of the 2RH1 structure, their closeness centrality would be 0.57 for Val
86, 0.57 for Asp 113, 0.44 for Phe 289, 0.67 for Asn 312 and 0.80 for Tyr 316.
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importance has been detected for nucleotide residues
in ribosomes (David-Eden and Mandel-Gutfreund 2008).
A further study from Nussinov and coworkers revealed
that, for non-enzyme proteins, although residues endowed
with high closeness-centrality are generally important
for fold and function, they are often not located within
their binding sites (del Sol et al. 2006a). The results of
our study are completely in line with these findings. In
particular, they revealed that the β2 AR residues endowed
with the highest closeness-centrality are located in the
core of the receptor. As a consequence, the receptor can
be likened to a bow tie (Figure 2), with a rather tight knot
of highly central and closely interacting residues and two
ends that fan out in two opposite directions: one toward
the extracellular space, which hosts the ligand binding
cavity, and one toward the cytosol, which hosts the G
protein binding cavity.
On a technical note, to transform each of several
experimentally solved structures of the β2 AR into a
graph representing a network of non-covalently connected
residues, we utilized the CSU program, written by Sobolev
and coworkers (Sobolev et al. 1999), to detect all non-covalent interactions present in each structure. Subse-
quently, we analyzed the closeness-centrality of each
residue is in the context of the entire network of inter-
actions by detecting the connectivity distance between
each residue of the receptor with every other residue.
This was done through an in-house implemented program
based on an established algorithm for the identification
of the shortest path that connects two nodes in a graph
(Dijkstra 1959). As a clarification, the connectivity distance
is not the actual physical distance between two residues,
but is defined as the number of first degree connections
(edges between the nodes) that separate two residues
(Figure 1c) – hence, two directly connected residues will
have a connectivity distance of 1, two residues that are
not directly connected but share a common directly
connected residue will have a connectivity of 2, and so
on and so forth.
Methods
Inferring non-covalent interactions
The identification of non-covalent interactions was
performed using the CSU program, which identifies
contacting atoms based on excluded solvent accessible
Figure 2 Three alternative views of two of the experimentally solved structures of the β2 AR, one solved in the inactive state (2RH1)
and one in an activated state (3P0G). A key residue in the activation of the receptor, namely Phe 2826.44, is shown with its non-hydrogen atoms
represented as spheres and colored in red for the 2RH1 structure and green for the 3P0G structure. The backbone of the receptor is schematically
portrayed as a ribbon for the 2RH1 structure and as a tube for the 3P0G structure and is colored with a continuous spectrum ranging from red at the
N-terminus to purple at the C-terminus, with TM1 in red/orange, TM2 in orange, TM3 in yellow, TM4 in yellow/green, TM5 in green, TM6 in blue and
TM7 in purple. In the views provided in panels b and c the receptor is rotated clockwise (when observed from the extracellular space) of 60° and 340°
degrees around its main axis with the respect to the view provided in panel a. The bow tie shape of the receptor is particularly evident from panel b.
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for the exact definition).
The source code for CSU was obtained from the
Weizmann Institute’s website (http://ligin.weizmann.ac.
il/space/programs/). To compile CSU, which is written in
Fortran, we used a 64-bit Ubuntu 10.04 virtual machine
hosted on the Amazon’s Elastic Compute Cloud (EC2)
platform. The output data from CSU was processed using
a custom-built wrapper script, written in the Python
scripting language. This script facilitated the analysis by
automatically identifying the number of chains present
in the processed protein and running CSU on all pairs in a
combinatorial manner. Furthermore, it parsed the output
of CSU interaction into a hashmap, which encapsulated all
the data relative to that interaction – The example shown
in Additional file 1: Figure S1 shows how a CSU output
line relative to a specific interaction would be transferred
into the a Python dictionary. Then, filters were applied to
the data to screen out any intra-residue interactions (e.g.
interactions within atoms of the same residue), as well as
covalent interactions between the backbone atoms of
neighboring residues. The resulting data represented only
non-covalent interactions between non-adjacent atoms.
Construction of a graph describing the network of
residue interactions and calculation of closeness-centrality
From the list of all non-convalent interactions between
non-adjacent atoms, through another custom-built Python
module, we constructed a graph representing all residue-
residue interactions found in the protein.
First, the atomic interactions were organized in the
form of residue-residue interactions. In particular, the
interaction between a given source residue (denoted asResidue1) and a given destination residue (denoted as
Residue2) was coded in the form a hashmap mapping the
two residues onto the list of all the atomic interactions
found between them, as the example in panel d of
Additional file1: Figure S1 shows. A residue-residue
interaction was always counted as one direct connection,
despite the number of atomic interactions found between
the two interacting residues.
Then, to determine the closeness-centrality, the con-
nectivity distance from that residue (a specific node in
the graph) to each other residue (each other node in the
graph) following the shortest path was determined
through Dijkstra’s algorithm (Dijkstra 1959). As explained
in the introduction, the term connectivity distance is
defined as the number of edges between the source and
the destination node, not the actual physical distance
between the nodes. For example, two nodes that share
one direct interaction will have a connectivity distance
of 1, while two nodes that do not directly interact but
share one or more interactions with a common node
will have a connectivity distance of 2. Dijkstra’s algorithm
takes a specific node and computes the shortest path
length to all other nodes in the graph by using a technique
called relaxation. Initially, the connectivity distance from
the source node to all other nodes is set as infinite.
Then, the graph is traversed starting from the source.
As new nodes are discovered in the process of traversing,
the shortest path values become updated. The process
continues until every node has been traversed, and the
values presented are the shortest paths.
Once the shortest value connectivity distances from
the source were obtained, the closeness-centrality of the
source residue was determined according to the equation
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residue.
GPCR residue identifier numbers
Throughout the paper, we referred to the β2 AR residues
through their sequence number followed by a superscript
indicating their GPCR residue identifier number. At this
purpose, GPCR residue identifier numbers for all the
β2 AR residues were calculated through a custom-built
Python module that annotated the list of closeness-
centrality data. Originally devised by Ballesteros and
Weinstein, this system provides a universal way of
identifying corresponding residues found in the 7 TMs
of all GPCRs by numbering. In particular, this objective
is achieved by assigning the identifier X.50, where X is
the TM number, to the residue found in a reference
alignment position chosen by the authors on the basis
of sequence identity consideration. All other residues
in the same TM domain are numbered relatively to the
reference position. In the β2 AR, the X.50 positions are
the following: 1.50, Asn 51; 2.50, Asp 79; 3.50, Arg
131; 4.50, Trp 158; 5.50, Pro 211; 6.50, Pro 288; and
7.50, Pro 323 (Ballesteros and Weinstein 1995).
Addition of hydrogen atoms
The identification of the non-covalent interactions did
not require the addition of hydrogen atoms to the crystal
structures, since CSU has been expressly designed to
implicitly account their presence. However, for the
preparation of Figures 1, 3, 4 and 5, we added hydrogenFigure 3 Interhelical hydrogen bonds within the “knot region” of the
active structure (3P0G). The residues that form interhelical hydrogen bond
The color of the carbon atoms reflects the sequence position of the residu
with TM1 in red/orange, TM2 in orange, TM3 in yellow, TM4 in yellow/gr
co-crystallized with the receptors are also shown as balls and sticks, with
as yellow dotted lines.atoms with the “protein preparation wizard” workflow
of the Schrödinger suite, to add hydrogen atoms and
calculate the protonation states of ionizable groups at
pH 7. The workflow also optimized the orientation of
hydroxyl groups, as well as Asn, Gln and His residues
(Schrödinger Suite 2012 ; Sastry et al. 2013).Preparation of the figures
All the figures representing three-dimensional structures
of proteins were prepared with the Schrödinger suite
(Schrödinger Suite 2012).Results
A total of 12 crystal structures have been solved for the
β2 AR, in complex with 7 different ligands (Figure 6). Our
study is based on the analysis of 7 of these structures, each
of which is representative of the complex between the
receptor and one of the 7 different ligands with which it
has been co-crystallized. In order to make the comparison
among different structures possible, we analyzed only the
portion of the receptor solved in all the studied structures,
expunging the residues that were solved only in a subset
of the structure – the resulting amino acid sequence of
the analyzed structures is shown in Additional file 1:
Figure S2. Specifically, the analyzed sequence comprised
the entire segment (including all the intervening loops)
from the beginning of TM1 to the end of TM4 and the
entire segment (including all the intervening loops) from
the beginning of TM5 to the end of helix 8 (H8), which isβ2 AR: a) The carazolol-bound inactive structure (2RH1); b) the
s are shown as balls and sticks, all the others are shown as thin tubes.
es and goes from red at the N-terminus to purple at the C-terminus,
een, TM5 in green, TM6 in blue and TM7 in purple. The ligands
their carbon atoms colored in gray. Hydrogen bonds are represented
Figure 4 View of the “knot region” of the β2 AR, with the cluster of interconnected aromatic residues highlighted: a) the carazolol-
bound inactive structure (2RH1); b) the active structure (3P0G). The residues that belong to the aromatic cluster are shown as balls and
sticks, all the others are shown as thin tubes. The color of the carbon atoms reflects the sequence position of the residues and goes from red at
the N-terminus to purple at the C-terminus, with TM1 in red/orange, TM2 in orange, TM3 in yellow, TM4 in yellow/green, TM5 in green, TM6 in
blue and TM7 in purple. The ligands co-crystallized with the receptors are also shown as balls and sticks, with their carbon atoms colored in gray.
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TM7 (Additional file 1: Figure S2).
In particular, the analyzed structures, identified through
their PDB ID, with their respective resolution indicated in
parentheses, are: a) 2RH1 (2.40 Å) (Cherezov et al. 2007;
Rosenbaum et al. 2007), 3D4S (2.80 Å) (Hanson et al.
2008), 3NY8 (2.84 Å) (Wacker et al. 2010), 3NY9 (2.84 Å)
(Wacker et al. 2010), and 3NYA (3.16 Å) (Wacker et al.Figure 5 View of the “knot region” of the β2 AR, with the P-I-F motif
b) the active structure (3P0G). The residues that belong to the P-I-F mot
The color of the carbon atoms reflects the sequence position of the residu
with TM1 in red/orange, TM2 in orange, TM3 in yellow, TM4 in yellow/gree
co-crystallized with the receptors are also shown as balls and sticks, with th2010), which were solved in the inactive state in complex
with the blockers carazolol (1), timolol (2), ICI 118551 (3),
a blocker recently identifies through virtual screening (4)
(Kolb et al. 2009), and alprenolol (5), respectively; b) 3PDS
(3.50 Å) (Rosenbaum et al. 2011), which was solved in
the inactive state in complex with the agonist FAUC 50,
a large compound covalently bound to a Cys residue
artificially introduced in place of His 932.64 in TM2 (6);highlighted: a) The carazolol-bound inactive structure (2RH1);
if are shown as balls and sticks, all the others are shown as thin tubes.
es and goes from red at the N-terminus to purple at the C-terminus,
n, TM5 in green, TM6 in blue and TM7 in purple. The ligands
eir carbon atoms colored in gray.
Figure 6 Molecular structures of the seven ligands crystallized with the β2 AR in the published structures. Compounds 1–5 are blockers,
while compound 6–7 are agonists. Of note, compound 6 is covalently bound to a Cys residue artificially introduced in place of His 932.64 in TM2.
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solved in complex with the agonist BI 167107 (7) and the
nanobody nb80. Between the two activated structures
of the receptor solved in complex with the agonist BI
167107, we chose 3P0G rather than 3SN6, although the
latter features the presence of a heterotrimeric G protein.
This choice was dictated by the fact the side-chains of
several amino acids that were solved for all the seven
analyzed structures, were not solved for 3SN6.
For brevity, throughout the Results and Discussion
sections of this article, we refer to the closeness-centrality,
defined by the formula in Figure 1d, simply as centrality.
Moreover, we identify all amino acid residues through
both their sequence number and their GPCR index
number – see methods for more information.
The most connected residues
Our first level of analysis focused on the identification
of the residues with the highest centrality in the seven
studied structures. As Figure 7 shows, plotting the centrality
value versus the residue numbers reveals the presence
of seven peaks corresponding to regions with highly
connected residues. Mapping on the crystal structures
the most highly connected residues – more specifically
the residues for which the centrality value was equal or
higher than a cutoff value set to the average plus the
standard deviation across all residues (centrality ≥ 0.255) –
reveals that each of these seven regions is located in
the middle of one of the seven transmembrane domains
of the receptor (Figure 8). The centrality values for the
mapped residues are numerically reported in Additional
file 1: Table S1, which reveals that most of the highlyconnected residues are located in the middle of TM2,
TM3, TM6 or TM7, while a substantially narrower number
of highly connected residues are located in the middle of
TM1, TM4 or TM5. There are no substantial differences
in the pool of residues with the highest centrality in the
seven analyzed structures. The only notable exception
concerns the activated structure (3P0G), for which residues
located toward the cytosolic end of the middle portion
of TM6 show a lower centrality when compared to their
counterparts in the inactive structures.
Differences in centrality between activated and
inactive structures
Our second level of analysis delved more deeply into
the study of the difference in centrality among the
seven structures. In particular, for each residue, we studied
the difference between the centrality detected for the
activated structure (3P0G) and each of the six inactive
structures. As the plot shown in Figure 9 reveals, there
is one region for which the centrality detected for the
active structure is markedly different from that of the
corresponding residues in the inactive structure. Mapping
on the crystal structures the residues with the most
marked differences in centrality – more specifically the
residues for which the difference in centrality exceeded
cutoff values set to the average plus or minus 2.5 times
the standard deviation across all residues (difference in
centrality ≥ 0.022 or ≤ −0.026) – reveals that the region
in which most of the differences are concentrated is
located toward the cytosolic end of TM6 (Figure 10 and
Additional file 1: Figure S3). More specifically, residues
located in this region show a higher centrality in the
Figure 7 Closeness-centrality of all residues in the seven analyzed structures. The seven peaks of high closeness-centrality identify residues
located in the middle of each of the seven transmembrane domains of the receptor. In particular, most of the residues characterized by high
closeness-centrality are located in the middle of TM2, TM3, TM6 and TM7.
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further region for which differences in centrality were
detected is the second intracellular loop, with one residue
that features a higher centrality in the inactive than
the activated structure (Pro 138) and one that acquires
centrality with the activation (Ser 143). Of note, this
domain was crystallized in an unstructured conformation
in the inactive structures and as a α-helix in the activated
structures (see panel c of Figure 2). Moreover the residue
located at the extracellular end of TM1 (Trp 321.33),
features a marked lower centrality in two of the analyzed
structures, namely 3NY9 and 3NYA, than the rest of the
analyzed structures – it is worth noting, however, that for
the 3NY9 structure the side chain of Trp 321.33 was not
solved. The numerical values of the difference in centrality
values for the mapped residues are numerically reported
in Additional file 1: Table S2.
Effect of the co-crystallized ligands on the centrality of
the β2 AR residues
In the first level of analysis, the structures were analyzed
without the co-crystallized ligands. Thus, in our second
level of analysis we studied the change in centrality
detected when the structures were analyzed with or
without the co-crystallized ligand. Because the ligandsin question are small molecules, we treated them as a
single residue. As the plot shown in Figure 11 reveals,
there is one major region for which the centrality is
markedly increased in the presence of the ligands.
Mapping on the crystal structures the residues most
markedly affected by the ligands – more specifically
the residues for which the difference in centrality was
equal or higher than a cutoff value set to the average
plus 2.5 times the standard deviation across all residues
(difference in centrality ≥ 0.015) – reveals that the region
in question comprises residues in EL2 and the adjacent
half of TM5 (Figure 12 and Additional file 1: Figure
S4). A closer examination of Figure 12 and Additional
file 1: Table S3 reveals that additional regions that acquire
centrality for the blocker-bound structures include TM3,
TM6, TM7 and EL3, while additional regions that acquire
centrality for the agonist-bound structures include TM1,
TM2, TM3, TM6, TM7 and EL1. Despite this partial
overlap, the pattern of residues that acquire centrality
in the presence of agonists or blockers is rather different.
Strikingly, there is little overlap between the residues
that acquire centrality in the presence of the ligand in
the blocker-bound structures and the agonist-bound
structures. In particular, only two residues are in common
between the two agonist-bound structures and some of
Figure 8 Three-dimensional representation of the β2 AR, showing the residues for which the detected closeness-centrality exceeded
the average plus the standard deviation of the values detected across all residues for the 2RH1 (panel a), 34DS (panel b), 3NY8 (panel
c), 3NY9 (panel d), 3NYA (panel e), 3PDS (panel f), and 3P0G (panel g) structures. The backbone of the receptor is schematically portrayed
as a ribbon colored with a continuous spectrum ranging from red at the N-terminus to purple at the C-terminus, with TM1 in red/orange, TM2 in
orange, TM3 in yellow, TM4 in yellow/green, TM5 in green, TM6 in blue and TM7 in purple. The non-hydrogen atoms of the shown residues are
represented as spheres, colored according to the same scheme illustrated for the backbone.
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2045.43. Moreover, the inactive structure crystallized with
the large, covalently bound, FAUC 50 agonist (3PDS)
shares two additional residues in common with some
of the blocker-bounds structures, namely Ala 2005.39,
Ser 2035.42 (Additional file 1: Table S3).Discussion
As mentioned, following the recent boom of GPCR
crystallography, several analyses of the molecular architec-
ture of the receptors were published (Jacobson and
Costanzi 2012; Katritch et al. 2012, 2013; Venkatakrishnan
et al. 2013; Mason et al. 2012). These studies focused
on the analysis of the individual residue-residue and
residue-ligand interactions found in the now numerous
experimentally elucidated structures of GPCRs. Even prior
to the flourishing of the field of GPCR structural biology,
through sequence alignments and homology modeling,
a number of studies reported hypotheses on the putative
individual interactions that kept together the structure
of the receptors and facilitated the interactions with
their ligands. Some of these studies were extended to
the entire GPCR superfamily (Ballesteros et al. 2001),
while others, such as those in the examples shown in the
cited references, were confined to the analysis of singlefamilies of receptors (Costanzi et al. 2004; Kim et al.
2003). The present analysis of the β2 AR complements
these studies by adding a description of the ability of
each residue of this prototypical GPCR to establish
direct or indirect relationships with all other residues
of the receptor.
Our study highlighted that the receptor resembles a
bow tie, with a rather tight knot in correspondence of
the region of the helical bundle deeply buried in the
middle of the plasma membrane, where the most central
residues are located (Figure 2). It is in the correspondence
of this knot that the most highly connected residues are
found. Of the seven transmembrane domains, those that
most actively contribute to keeping the knot tight are
the more internal TM2, TM3, TM6 and TM7 (Figure 6).
A recent detailed analysis of the crystal structures of all
GPCRs revealed the existence of a consensus scaffold
of non-covalent residue-residue contacts between 36
topologically equivalent residues common to all the solved
structures [(Venkatakrishnan et al. 2013)]. Notably, our
analysis based on graph theory revealed that 25 out of
these 36 topologically equivalent residues are residues
endowed with high centrality in the knot region of the
receptor.
From the knot, two ends characterized by lower centrality
values fan out in two opposite directions, one toward
Figure 9 Difference in closeness-centrality between the activated structure (3POG) and the rest of the analyzed structures, which are
all inactive: TM6 looses centrality with activation.
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These regions are endowed with lower centrality values
and correspond to the two well characterized cavities
found in GPCRs: as crystallographic evidence showed
for β2 AR and rhodopsin, the cavity opened toward the
cytosol hosts the site to which the C-terminus of the α
subunit of the G protein binds, while the one opened
the toward the extracellular milieu hosts the ligand
binding site (Rasmussen et al. 2011b; Scheerer et al.
2008; Choe et al. 2011; Standfuss et al. 2011; Deupi
et al. 2012; Singhal et al. 2013). In light of the cavities
present within them and their more peripheral location,
it is not surprising that, as mentioned, the two ends
feature residues endowed with a substantially lower
network centrality than the residue in the knot. This
observation is in line with the finding of Nussinov and
coworkers that, although for enzymes the residues endowed
with the highest centrality typically line binding cavities,
the same is not necessarily true for other proteins (del Sol
et al. 2006a). Conversely, in a different study in which
graph-theory was not applied to the analysis of structures
but to the examination of an alignment of GPCR sequences,
it was found that the residues that, for class A and class
C receptors, share the highest mutual information are
located in the cavity opened toward the extracellular
milieu (Fatakia et al. 2009).GPRS are inherently flexible molecules that exist in a
continuum spectrum of conformations associated with
different levels of activation and, most likely, responsible
for the triggering of different signaling cascades (Kobilka
and Deupi 2007; Yao et al. 2006; Swaminath et al. 2005;
Swaminath et al. 2004; Kim et al. 2013; Nygaard et al.
2013; Bokoch et al. 2010). Hence, the network centrality of
the residues that compose them changes as a consequence
of the conformational rearrangements of the receptor.
Specifically, in our study, when comparing the network
of connections of the β2 AR residues in activated versus
inactive structures, we observed a marked loss in centrality
for the residues located in the cytosolic half of TM6
(Figure 10). This result is completely in line with what
was eloquently illustrated by the crystal structure of the
β2 AR in complex with a Gs heterotrimer as well as
those of rhodopsin in complex with the C-terminal
fragment of the α subunit of transducing [Refs]. According
to these structures, the most obvious structural change
consequent the activation of the receptor is an opening
of the cytosolic portion of the helical, which is absolutely
necessary for the formation of a docking cavity for the
C-terminus of the G protein and occurs through a dramatic
outward swing of the entire half of TM6 that faces the
cytosol. In particular, the cytosolic end of TM6 moves
away of about 14 Å from the space that it occupies when
Figure 10 Three-dimensional representation of the β2 AR,
showing the residues for which the difference in closeness-
centrality between the activated structure (3POG) and the rest
of the analyzed structures exceeded the average plus 2.5 times
the standard deviation of the values detected across all residues –
separate figures for the individual structures are given in
Additional file 1: Figure S3. The backbone of the receptor is
schematically portrayed as a ribbon colored with a continuous spectrum
ranging from red at the N-terminus to purple at the C-terminus, with
TM1 in red/orange, TM2 in orange, TM3 in yellow, TM4 in yellow/green,
TM5 in green, TM6 in blue and TM7 in purple. The non-hydrogen atoms
of the shown residues are represented as spheres, colored according to
the same scheme illustrated for the backbone.
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2011a).
The end of the bow tie that stems from the knot
toward the extracellular milieu, as mentioned, harbors
the ligand-binding cavity. As recently reviewed, in each
receptor this cavity is endowed with a particular shape
and size, ranging from the large and widely open cleft
found in peptide-binding receptors to the tight and
more enclosed site found in the muscarinic receptors
(Jacobson and Costanzi 2012). As ligands bind to their
receptors, they establish contacts with the residues of the
ligand-binding cavity, therefore increasing their centrality.
For the β2 AR, our analysis revealed that agonists and
blockers contribute to enhancing the centrality of substan-
tially different sets of residues (Figure 12). In all likelihood,the pattern of connectivity fostered by agonists is the
cause of the stabilization of specific signaling states of
the receptor. This is in line with the experimental ob-
servation that agonists and blockers of GPCRs typically
show patterns of receptor-ligand interactions that are
not completely overlapping, as the crystal structures
and a number of detailed analyses highlighted (Rasmussen
et al. 2011a; Deflorian et al. 2012; Xu et al. 2011; Jacobson
and Costanzi 2012; Venkatakrishnan et al. 2013; Katritch
et al. 2013).
Closeness-centrality values indicate the most connected
residues. However, they do not reveal the details of the
interactions established by the residues. Hence, following
the analysis based on graph theory, we performed a visual
analysis of the first-degree residue-residue connections
for the residues found in the knot. In the remainder of
the Discussion, we describe the main features highlighted
by this analysis and examine a putative role of residues
found in the knot in linking agonist binding to receptor
activation that seem plausible in light of the available
structural information.
Our visual analysis revealed that many of the first-
degree contacts of the residues in the knot are established
with other residues also found in the knot. We postulate
that these first-degree connections among knot residues
are likely responsible for maintaining the α-helical structure
of the transmembrane domains and for keeping together
the heptahelical bundle. Concerning their nature, our
visual inspection revealed that only few of them are
interhelical hydrogen bonds (Figure 3). Specifically,
interhelical hydrogen bonds were detected between the
pairs Asn 511.50 – Ser 3197.46 (backbone), Ser 742.45 – Trp
1584.50, Asp 792.50– Ser 3197.46, and Asp 1133.32 – Tyr
3167.43 for all the analyzed structures. An additional
hydrogen bond was detected between the pair Asp
792.50 – Asn 3227.49 for both agonist-bound structures
(3PDS and 3P0G), and was caused by a rearrangement
of the side chain of Asn 3227.49 and the protonation
state assigned to Asp 792.50. Of note, in agreement with
what was suggested in the literature (Ghanouni et al.
2000; Vanni et al. 2010), Asp 792.50 was predicted to be
protonated for the inactive structures and deprotonated
for the agonist-bound structures by the hydrogen-bond
network optimization tool that we employed. Moreover,
two additional hydrogen bonds were detected between
the pairs Asp 792.50 – Ser 1203.39, Ser 2075.46 – Thr1183.37
for the agonist-bound activated structure only (3P0G),
which are due to the considerable rearrangements that Ser
1203.39 and Ser 2075.46 undergo upon activation.
The other contacts among the residues in the knot
typically involve hydrophobic atoms. For instance, aromatic
contacts interconnect a cluster of aromatic residues
that comprises Trp 1093.28, Phe 2085.47, Phe 2826.44,
Phe 2826.44, Trp 2866.48, Phe 2896.51, Phe 2906.52, and
Figure 12 Three-dimensional representation of the β2 AR, showing the residues for which the difference in closeness-centrality detected
when the analyses were performed in the presence or the absence of ligands exceeded the average plus 2.5 times the standard deviation
of the values detected across all residues, for all the analyzed blocker-bound structures (panel a), as well as the agonist-bound 3PDS (panel
b) and 3POG (panel c). Separate figures for the individual blocker-bound structures are given in Additional file 1: Figure S4. The backbone
of the receptor is schematically portrayed as a ribbon colored with a continuous spectrum ranging from red at the N-terminus to purple at the
C-terminus, with TM1 in red/orange, TM2 in orange, TM3 in yellow, TM4 in yellow/green, TM5 in green, TM6 in blue and TM7 in purple. The
non-hydrogen atoms of the shown residues are represented as spheres, colored according to the same scheme illustrated for the backbone.
Figure 11 Change in closeness-centrality detected when the structures are analyzed with or without ligands. With the exception of Cys
191 and Ser 204, there is complete lack of overlap between the residues that acquire centrality in the blocker-bound structures and those that
acquire centrality in the activated agonist-bound structure (3P0G).
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are also found in the case of three notable interacting
residues dubbed the “P-I-F” motif, namely, Pro 2115.50,
Ile 1213.40 and Phe 2826.44 (Figure 5) – note that the latter
residue also belongs the above-mentioned aromatic
cluster. Residues of the P-I-F are conserved in many
aminergic receptors and connect TM3, TM5 and TM6
(Rasmussen et al. 2011a; Wacker et al. 2013). As Kobilka
and coworkers demonstrated, in the agonist-bound fully
activated structure of the receptor, Phe 2826.44 of the P-I-F
motif shows a major conformational change with respect
to the blocker-bound inactive structures (Figure 2)
(Rasmussen et al. 2011a). Experimental evidence shows
that mutation of Phe 2826.44 leads to a receptor with
higher increased or decreased basal activity, depending
on the substituting amino acid (Chen et al. 2002).
Hence, one can speculate that this event could be the
likely trigger of the outward swing of the entire portion
of TM6 upstream of the phenylalanine, i.e. the entire
half of TM6 that faces the cytosol.
In the β2 AR, the P-I-F motif is not in direct contact
with the ligand. Thus, it is reasonable to venture that
some of the residues that acquire centrality upon agonist
binding may provide a link between the agonist, the P-I-F
motif and TM6. Two residues belonging to the above-
mentioned aromatic cluster found in the knot region,
namely Trp 2866.48 and Phe 2906.52, are among those that
acquire connectivity in the presence of agonists but not
blockers. Within this cluster, the aromatic residue at
position 6.48, which is a staple of most class A GPCRs, is
one of the most studied residues across the superfamily.
For many receptors, although not all, mutations of this
residue have been reported to significantly alter the
activation process. For some GPCRs, for instance the
purinergic P2Y1 receptor, its mutation to alanine leads
to a receptor that can no longer be activated by agonists,
despite their binding (Costanzi et al. 2004). For others, such
as the TRH-R1 receptor, it leads to a constitutively active
receptor (Deflorian et al. 2008; Sun and Gershengorn
2002). Finally, for others yet, such as the serotonin 5-HT4
receptor, it suppresses basal activity but does not alter
the maximal activity of the natural agonist (Pellissier
et al. 2009). From the structural point of view, on the
basis of early biophysical experiments, this residue was
hypothesized to undergo a substantial conformational
change with the activation of the receptor and was
dubbed the “rotamer toggle switch” (Shi et al. 2002;
Yao et al. 2006). Among the GPCR structures that were
solved in at least a partially activated state, this putative
conformational change is most evident for the adenosine
A2A receptor, although perhaps not as dramatic as
expected (Xu et al. 2011; Katritch et al. 2013). Conversely,
for the β2 AR, the conformational change of Trp 286
6.48
and the adjacent Phe 2906.52 captured through X-raycrystallography are subtler (Figure 4) (Rasmussen et al.
2011a; Rasmussen et al. 2011b). Hence, Trp 2866.48 and
Phe 2906.52 may not be the primary links between agonists
and the P-I-F motif.
Conversely, another residue that in our analysis acquires
centrality only in the presence of agonists, namely Ser
2075.46, is likely to provide a stronger physical link
between agonist binding and the conformational rearrange-
ment of the P-I-F motif. As the comparison between
active and inactive structures of the β2 AR clarified, the
largest movement detected in the ligand binding cavity
as a consequence of the activation of the receptor is a
shift of the portion of TM5 centered around this serine
residue, which moves 2.1 Å toward the center of the
helical bundle, attracted by the aromatic hydroxyl groups
of the bound agonists (Figure 3) (Rasmussen et al. 2011a;
Rasmussen et al. 2011b). As hypothesized by Rasmussen
and coworkers, this rearrangement of Ser 2075.46, which
through a series of conformational searches coupled with
statistical analyses we had predicted to be associated with
the activation of the β2 AR prior to the solution of the
activated structure (Vilar et al. 2011b), may trickle
down to Pro 2115.50 of the P-I-F motif, located one
helix turn below Ser 2075.46. In turn, this could be the
cause of the consequent rearrangement of the two
remaining residues of the motif, (Figure 5) (Rasmussen
et al. 2011a), which is likely to be responsible for triggering
the large outward swing of the portion of TM6 upstream
of Phe 2826.44.Conclusions
In conclusion, our analysis of the structure of the β2
AR based on graph theory highlighted that the receptor
resembles a bow tie, with a knot of closely interconnected
residues and two ends that fan out in two opposite direc-
tions: one toward the extracellular space, which hosts the
ligand binding cavity, and one toward the cytosol, which
hosts the G protein binding cavity. Moreover, the results
highlighted how the intricate network of interactions
among the residues of the receptor is affected by the pres-
ence of agonists or blockers as well as the conformational
rearrangements concomitant with the activation process.Additional file
Additional file 1: Table S1. Residues showing the highest network
centrality; Table S2. Difference in network closeness-centrality with
respect to 3POG; Table S3. Change in network centrality when the
structures are analyzed with or without ligands; Figure S1. Example
showing how non-covalent interactions are stored in Python dictionary.
Figure S2. Amino acid sequence of the β2 AR structures subjected to the
analysis; Figure S3. The six individual structures that are shown superimposed
in Figure 10; Figure S4. The five individual structures that are shown
superimposed in panel a of Figure 12.
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